Controlled release dosage forms
First Claim
Patent Images
1. A stable controlled release monolithic coating composition for use in coating a pharmaceutical oral dosage form, said coating comprising:
- a) an aqueous dispersion of a neutral ester copolymer without any functional groups;
b) a poly glycol having a melting point greater than 55°
C., and c) one or more pharmaceutically acceptable excipients;
wherein said coating composition is coated onto said pharmaceutical oral dosage form and cured at a temperature at least equal to or greater than the melting point of said poly glycol.
24 Assignments
0 Petitions
Accused Products
Abstract
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
124 Citations
40 Claims
-
1. A stable controlled release monolithic coating composition for use in coating a pharmaceutical oral dosage form, said coating comprising:
-
a) an aqueous dispersion of a neutral ester copolymer without any functional groups;
b) a poly glycol having a melting point greater than 55°
C., andc) one or more pharmaceutically acceptable excipients;
wherein said coating composition is coated onto said pharmaceutical oral dosage form and cured at a temperature at least equal to or greater than the melting point of said poly glycol. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
- 11. The stable controlled release coating composition of 10 wherein said polyethylene glycol or derivative there of is present in an amount of from about 0.1% to about 5% by weight of the coat composition.
-
38. A stable controlled release monolithic coating composition for use in coating a pharmaceutical oral dosage form, said coating comprising an aqueous dispersion of Eudragit NE30D, polyethylene glycol 8000, hydroxypropyl methylcellulose, talc, simethicone, titanium dioxide, and polyoxyethylene sorbitan mono-oleate, said Eudragit NE30D is present in an amount of from about 1% to about 35% by weight of the coat composition, said polyethylene glycol is present in an amount of from about 0.1% to about 3% by weight of the coat composition, said hydroxypropyl methylcellulose is present in an amount of from about 0.1% to about 6% by weight of the coat composition , said talc is present in an amount of from about 0. 1% to about 7% by weight of the coat composition, said simethicone is present in an amount up to about 0.5% by weight of the coat composition, said polyoxyethylene sorbitan mono-oleate is present in an amount of up to about 0.5% by weight of the coat composition, said titanium dioxide is present in an amount of from about 0.% to about 2% by weight of the coat composition;
- and composition is coated onto said pharmaceutical oral dosage form and cured at a temperature at least equal to or greater than the melting point of said polyglycol.
- View Dependent Claims (39)
-
40. A controlled release oral dosage form comprising:
-
a) a core, wherein said core comprises;
i) an effective amount of at least one therapeutically active agent, and ii) one or more first pharmaceutically acceptable excipients, and b) a stable controlled release monolithic coating composition for coating said core, said coating composition comprising;
i) an aqueous dispersion of a neutral ester copolymer without any functional groups;
ii) a poly glycol having a melting point greater than 55°
C., andiii) one or more second pharmaceutically acceptable excipients;
wherein said coating composition is coated onto said core and cured at a temperature at least equal to or greater than the melting point of the poly glycol.
-
Specification